Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
January 08, 2024 07:30 ET
|
Arbutus Biopharma Corporation
Additional data from two on-going Phase 2a clinical trials evaluating imdusiran, our RNAi therapeutic, as a cornerstone therapy in combination with other compounds expected in 2024 Initiation of a...